ERO1α as a Potential Drug Target for Breast Cancer: A Systematic Review of Current Evidence

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Hypoxia, oxidative stress, and protein misfolding promote tumor progression and therapy resistance.
• Endoplasmic Reticulum Oxidoreductin 1 Alpha (ERO1α) is crucial for redox homeostasis, disulfide bond formation, and reactive oxygen species generation.
• Elevated ERO1α correlates with aggressive breast cancer, metastasis, and poor prognosis, yet lacks clinical inhibitors.

Purpose of the Study:

• To systematically review the multifaceted roles of ERO1α in breast cancer.
• To analyze ERO1α's involvement in hypoxia response, angiogenesis, immune evasion, and ferroptosis resistance.
• To consolidate current knowledge on ERO1α inhibitors and therapeutic strategies.

Main Methods:

• Systematic literature review and analysis of existing research on ERO1α in breast cancer.
• Integration of molecular mechanisms linking ERO1α to tumor progression.
• Examination of preclinical data on ERO1α inhibitors and therapeutic approaches.

Main Results:

• ERO1α significantly contributes to tumor aggressiveness, metastasis, and resistance to therapies.
• ERO1α influences key pathways including VEGF-A maturation and PD-L1-mediated immune suppression.
• ERO1α plays a role in resistance to ferroptosis, a form of programmed cell death.

Conclusions:

• ERO1α is a critical mediator of redox-dependent pathways in breast cancer.
• ERO1α represents a promising therapeutic target and potential prognostic biomarker.
• Further development of ERO1α inhibitors is warranted for targeted breast cancer interventions.